NCT04128683View on ClinicalTrials.gov

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

September 6, 2023

Study Completion Date

January 1, 2025

Conditions
Anorexia Nervosa
Interventions
DRUG

amisulpride

Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

DRUG

bromocriptine

Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

DRUG

Placebo

Placebo pill with no active drug ingredients

Trial Locations (1)

92121

University of California San Diego, San Diego

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, San Diego

OTHER

NCT04128683 - Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa | Biotech Hunter | Biotech Hunter